Perplexity Can Now Access Your Apple Health Data to Answer Medical Questions

Perplexity launched Perplexity Health, a health-data connector suite that aggregates data from Apple Health, Fitbit, Ultrahuman, Withings and EHRs covering more than 1.7 million care providers, with Oura and Function integrations coming soon; rollout on Perplexity Computer is starting for Pro and Max users in the U.S. The tool tracks biomarkers and trends, answers health questions using records/wearables, and enables AI agents to build personalized fitness and nutrition plans. Perplexity emphasizes encrypted data, strict access controls, user deletion tools, and says health data won't be used to train models or sold; it also formed a Health Advisory Board to vet clinical safeguards.

Analysis

The most important structural shift is not a single vendor integration but the acceleration of AI agents consuming continuous consumer health telemetry — that changes economics from one-off device sales to recurring, permissioned data services. Over 12–36 months this will raise ARPU for platform owners who control sensor-to-OS plumbing (higher yield per device of $1–3/mo is plausible) while creating a multi-layered marketplace for analytics, care pathways, and identity services.

Second-order winners will be vendors of identity/access controls and endpoint security: health data raises both breach impact and compliance spend, so expect security budgets to reallocate toward telemetry protection. Conversely, standalone telehealth triage businesses that monetize visits rather than data may see volume compression as AI-first, personalized guidance reduces low-acuity demand over 1–2 years.

Regulatory and litigation risk is the dominant latent threat. Within months we can see targeted enforcement actions or class suits over clinical advice and data use; within 1–3 years a patchwork of stricter consent/HIPAA interpretations or device/FDA rules could materially raise compliance costs. A security breach would be a sharp, immediate catalyst — stock reactions would be binary and severe for any exposed player.

The consensus focus on feature headlines misses the economics of trust: platforms that can execute on-device processing and granular consent will win share even if feature parity exists. That makes hardware/OS incumbents defensible — but also the prime targets for antitrust and privacy scrutiny, creating concentrated upside and outsized tail risk simultaneously.

Key Decisions for Investors

• Buy AAPL (2–3% portfolio) — 6–12 month horizon. Rationale: incremental services ARPU and stickiness from health telemetry should support multiple expansion; target +12–18% upside. Hedge: buy 5% OTM puts for tail protection if regulatory headlines spike; expected cost ~1–2% of position value.
• Long CRWD or OKTA (select one; 3–6 month horizon) — play the surge in enterprise spend on identity and telemetry security. Position size 1–1.5% each; asymmetric upside 20–30% if adoption accelerates, downside capped to earnings/multiple compression risk (~15–20%). Consider call spreads to reduce premium outlay.
• Short TDOC (or similar virtual-care pure plays) — 3–9 month horizon. Thesis: AI-first self-triage and aggregated health dashboards compress low-acuity visit volumes and pricing. Target -25–35% move; risk is consolidation/partnership upside. Size small (<=1% portfolio) and use CDS/put options where available to limit equity exposure.
• Pair trade: Long CRWD (security) / Short TDOC (telehealth) — 3–9 months. This expresses the rotation from visit-based monetization to platform & security spend. Aim for net directional skew positive ~15–20% with controlled downside via options collars on each leg.